基本信息
views: 143
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
NAME: Richard Moriggl
eRA COMMONS USER NAME (credential, e.g., agency login): orcid.org/0000-0003-0918-9463
POSITION TITLE: Dr. (PhD) Full Prof. University of Veterinary Medicine, Vienna, Full Prof. Medical University Vienna, Vienna, Austria
EDUCATION/TRAINING
INSTITUTION AND LOCATION DEGREE Completion Date FIELD OF STUDY
University of Freiburg, Institute of Experimental Cancer Research, Freiburg, Germany PhD 1994-1997 Molecular Biology, Biochemistry
St. Jude Children’s Research Hospital, Memphis, TN, U.S.A. Postdoc 1997-2000 Immunology, Hematopoiesis
Institute of Molecular Pathology (IMP), Vienna, Austria Postdoc 2000-2005 Cancer Research and Signaling Pathways
Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Director 2005 to 2018 Cancer Research and Cytokine Signaling, Targeting of Core Cancer Pathways with Focus on JAK-STAT Inhibition
University of Veterinary Medicine, Vienna, Austria
Medical University Vienna, Vienna, Austria Full Professor 2014 ongoing Functional Cancer Genomics
Core Cancer Pathway Targeting
A. Personal Statement and Research Focus on JAK-STAT and Cancer Mouse Models
The JAK-STAT pathway is a central core cancer pathway that can drive other essential core cancer pathways such as survival, cell cycle progression, PI3K-AKT-mTOR signalling, attachment/invasion or angiogenesis. Furthermore, we study cancer through comparative pathology studies using innovative animal models, patient sample analysis combined with high end technology analysis. Mostly hematopoietic cancers are studied, but the group has also projects on Ewing sarcoma and other solid cancers. We explore targeted inhibition in mice and patients together with several international collaboration partners. We moved into lead structure development, testing and new compound screening to target key oncogenic transcription factors. We assembled a comprehensive set of test systems for cancer models combining them with targeted therapy approaches. We filed necessary ethical animal or patient sample work approval licences with government authorities to exploit translational cancer research and comparative medicine questions. Our long term mission is to molecularly explore cancer models and to come up with new therapies through our work with animal models, always spiked with patient findings (including several mammalian species) to perform a reality check to work closely with disease relevant focus.
Voluntary reviewer for international journals as listed also since 2017 via Publons and evaluator for many international research organisations or involved in grant peer reviewer panels.
B. Positions and Honors (Scientific Education and Career History):
1988 - 1993 Study of Biotechnology at the Technical College, Bingen, Germany and Diploma work, Institute of Cell and Molecular Biology, CNRS, Strasbourg, France
1993 - 1997 Doctoral thesis; First at the Friedrich Miescher Institute, Basel,
Switzerland, then continuation at Department of Biology, University of
Freiburg, Institute for Experimental Cancer Research, Germany
1997 - 2000 Postdoctoral Howard Hughes fellowship at St. Jude Children’s Research Hospital, Memphis, TN, USA
2000 – 2002
2002-2005 Marie Curie Host Industry Fellowship, Institute of Molecular Pathology, Vienna, Austria
Postdoctoral fellow at Institute of Molecular Pathology, Vienna, Austria
since 2005
since 2013 to 12/2018 Director Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
LBI-CR Renewal and second funding period with five long term Partner Institutes
since 2014 Full Prof. for Functional Cancer Genomics (C4 / full professorship), Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Medical University Vienna
Fellowships and Appointments:
1997 - 2000 Howard Hughes Medical Institute Postdoctoral Fellowship
2000 - 2002 Marie Curie Host Industry Fellowship
2003 “Habilitation/Venia Docendi” for Molecular Biology, Medical University Vienna
2005 Offered group leader position, Leibniz Institute for Age Research, Jena
since 2005 Director, Ludwig Boltzmann Institute for Cancer Research
since 2014 Full Prof. with the two medical universities Vienna, Austria
2019/2020 Academic Editor for a Special Issue for Cancers "Targeting STAT3 and STAT5 in Cancer"
03/2020 Associate Editor for Cytokine
Research Interests
Papers共 355 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Qianze Dong, Yang Wang,Yan Xiu, Xiaogang Wu, Stacey O'Neill,Howard Meyerson,Suske Tobias,Richard Moriggl,Shimin Hu,Wei Wang,Chen Zhao
BRITISH JOURNAL OF HAEMATOLOGYno. 6 (2024): 2487-2491
Klara Klein,Sebastian Kollmann, Angela Hiesinger,Julia List, Jonatan Kendler,Thorsten Klampfl, Mehak Rhandawa,Jana Trifinopoulos,Barbara Maurer,Reinhard Grausenburger, Christof A Betram,Richard Moriggl,
Torben Redmer,Martin Raigel,Christina Sternberg,Roman Ziegler, Clara Probst, Desiree Lindner,Astrid Aufinger,Tanja Limberger,Karolina Trachtova,Petra Kodajova,Sandra Högler,Michaela Schlederer,
Molecular Cancerno. 1 (2024): 1-21
Jana von Jan,Sanna Timonen,Till Braun,Qu Jiang,Aleksandr Ianevski,Yayi Peng,Kathleen McConnell,Paola Sindaco,Tony Andreas Müller, Sabine Pützer, Hanna Klepzig,Dennis Jungherz,
Blood (2024)
Nikolaus Fortelny,Matthias Farlik, Victoria Fife,Anna-Dorothea Gorki,Caroline Lassnig,Barbara Maurer,Katrin Meissl,Marlies Dolezal, Laura Boccuni, Aarathy Ravi Sundar Jose Geetha, Mojoyinola Joanna Akagha, Anzhelika Karjalainen,
crossref(2023)
Diaaeldin I Abdallah,Elvin D de Araujo, Naman H Patel, Lina S Hasan,Richard Moriggl,Oliver H Krämer,Patrick T Gunning
Exploration of Targeted Anti-tumor Therapy (2023): 757-779
crossref(2023)
Load More
Author Statistics
#Papers: 351
#Citation: 14236
H-Index: 64
G-Index: 110
Sociability: 8
Diversity: 3
Activity: 116
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn